First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Array BioPharma
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01828034
First received: April 5, 2013
Last updated: January 7, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2017
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)